Dr. Jan Lichtenberg, CEO and co-founder of InSphero, says that the investment round enables InSphero to leverage the successful customer implementations, robust validation data, and growing scientific evidence to become the gold standard in the field of 3D cell-based assays.
“This investment is an affirmation of InSphero’s valuable, more predictive liver, islet and tumor model systems for use throughout the drug development process,” said Lichtenberg. “The family office behind HP WILD HOLDING AG brings to InSphero long-term perspective as well as decades of experience building global brands and driving operational excellence. Their financial commitment is also strengthened by an established international network that will help us better serve growing global demand for microtissues and services, particularly in North America and Asia.”
The proceeds of the financing round will be invested to expand InSphero’s North American scientific staff and operations into a state-of-the art bio-production facility; increase the variety of model systems available to customers across different industries; and to develop new products including InSphero’s Body-on-a-Chip technology and personalized-medicine kits to maturity.
InSphero’s pipeline includes 3D liver, skin, heart, brain and tumor models developed for toxicity testing and disease modeling, as well as next-generation 3D cell culture platforms.
For more information about InSphero, visit www.insphero.com.